



# ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: [www.americasblood.org](http://www.americasblood.org)

2021 #8

March 5, 2021

## INSIDE:

NIH Ends CCP Trial for ER Patients with Mild Symptoms .....	2
Third COVID-19 Vaccine Gets FDA Emergency Use Authorization .....	3
RESEARCH IN BRIEF ....	4
COVID-19 Convalescent Plasma Updates .....	5
Upcoming ABC Webinars – Don't Miss Out! .....	5
Call for ABC Committee Nominations Deadline Extended .....	6
Register Today for ABC's Annual Meeting .....	6
INFECTIOUS DISEASE UPDATES .....	7
COMPANY NEWS .....	7
CALENDAR .....	8
POSITIONS .....	8

**Please Note:** The ABC Newsletter will not be published on March 12<sup>th</sup>. We will resume regular publication on March 19<sup>th</sup>. Thank you for your continued interest.

## ABC Announces 2021 Advocacy Agenda

America's Blood Centers (ABC) in consultation with its Board of Directors and Policy Council has published its [2021 Advocacy Agenda](#). It will focus on ABC's efforts to promote the value of blood to patients, communities, and the nation's healthcare system. Highlights of the agenda that ABC is advocating for include:

- ensuring community blood centers are a part of emergency preparedness. The essential role of the U.S. blood supply must be considered by federal, state, and local officials both from the beginning and throughout the duration of disasters including public health emergencies;
- the development of a public-private partnership to increase public awareness and education regarding blood donation, particularly with younger donors. This is part of a broader effort to raise awareness of the need for blood donation and to ensure a robust and resilient donor base; and
- the elimination of Zika testing requirements. ABC remains committed to ensuring data support U.S. Food and Drug Administration (FDA) mandated testing in an overall commitment to evidence-based testing requirements.

Additionally, ABC will continue to support:

- the prioritization of blood donation as a national imperative through:
  - establishing targeted federal initiatives to support increased diversity in the donor base such as funding for increased molecular red blood cell typing for patients with Sickle Cell Disease receiving frequent donations; and
  - funding social science research on donor and non-donor behaviors and motivations;
- recognizing the vital role of blood to the nation's healthcare system by:
  - exploring funding mechanisms to facilitate implementation of safety and technology measures when mandated by FDA, such as the recent platelet bacterial detection guidance, or when market incentives otherwise do not exist;
  - increasing federal resources for data on the collection and utilization of blood components as needed to support evidence-based decision making in federal policy; and

(continued on page 2)



### ABC 2021 Advocacy Agenda (continued from page 1)

- expanding the availability of blood components to patients at the end of life by modifying hospice reimbursement rates to reflect the added cost of providing blood components;
- reducing unnecessary and burdensome regulations that stifle innovation by:
  - applying evidence-based decision-making to FDA testing requirements to ensure testing burdens are justified by commensurate increases in safety;
  - advocating for FDA approval of extended shelf life for cold stored platelets; these products are particularly important for rural areas and in trauma with massive bleeding;
  - revising interstate transfer of products licensing regulations to reduce the time to process the application and allow interim licensure following a timely initial review, as these products are already acceptable for sale and use in the state of manufacture;
  - eliminating the need for blood centers to discard a safe blood donation if there is an error stemming from internal processes if the error has no influence on the safety, purity, or potency of the donation;
  - revisiting FDA's policy on the acceptance of international data for use in the approval of new products, technologies, and blood industry policies and procedures;
  - encouraging regulators to establish donor policies which promote inclusivity with research-based donor-screening alternatives based on individual behavior, not sexual or gender identity, to provide equivalent or superior transfusion safety;
  - lowering the U.S. Platelet Content Requirement (PCR), a minimum number of platelets per unit, in line with international standards; and
  - implementing a rational, flexible approach to the regulation of plasma products, advocating that the FDA license recovered plasma to give blood centers the ability to move plasma from transfusable to further manufacture as demanded by clinical need.

The complete 2021 advocacy agenda is available for download on the ABC public [website](#). ABC encourages all members to review this document. Please [contact](#) ABC Senior Director of Federal Government Affairs Diane Calmus, JD for questions or additional information. ♦

### **NIH Ends CCP Trial for ER Patients with Mild Symptoms**

The National Institutes of Health (NIH) [announced](#) on March 2<sup>nd</sup> that the “Clinical Trial of COVID-19 Convalescent Plasma of Outpatients” (C3PO) has “halt[ed].” An NIH news release stated that “[a]n independent data and safety monitoring board (DSMB) met on Feb. 25, 2021 for the second planned interim analysis of the trial data and determined that while the convalescent plasma intervention caused no harm, it was unlikely to benefit this group of patients. After the meeting, the DSMB recommended that the National Heart, Lung, and Blood Institute (NHLBI), part of NIH, stop enrolling new patients into the study. NHLBI did so immediately.”

The study included 47 hospital emergency departments nationwide and “had enrolled 511 of the anticipated 900 participant recruitment goal.” The participants were adults “who came to an emergency department with mild to moderate symptoms they had for a week or less. These patients also had at least one risk factor associated with severe COVID-19, such as obesity, hypertension, diabetes, heart disease, or chronic lung disease, but none were ill enough at the time to be hospitalized.” According to the news release, “researchers tracked whether the participants needed to seek further emergency or urgent care, had to be hospitalized,

(continued on page 3)



## NIH Ends ER CCP Trial (continued from page 2)

or died within 15 days of entering the trial. The recent data analysis from the study indicated no significant difference in the proportion of participants who experienced any one of these outcomes. Even if enrollment continued, this trial was highly unlikely to demonstrate that COVID-19 convalescent plasma prevents progression from mild to severe illness in at-risk emergency department non-hospitalized participants.”

(Source: NIH News [Release](#), 3/2/21) ♦

## Third COVID-19 Vaccine Gets FDA Emergency Use Authorization

The U.S. Food and Drug Administration (FDA) designated [emergency use authorization](#) (EUA) for Janssen’s, the pharmaceutical companies of Johnson & Johnson, COVID-19 vaccine. The EUA decision followed a positive recommendation from the agency’s Vaccines and Related Biological Products Advisory Committee (VRBPAC), which met on February 26<sup>th</sup> to review data submitted by Janssen for its COVID-19 vaccine. “The authorization of this vaccine expands the availability of vaccines, the best medical prevention method for COVID-19, to help us in the fight against this pandemic, which has claimed over half a million lives in the United States,” said Acting FDA Commissioner Janet Woodcock, MD, in an agency [news release](#). “The FDA, through our open and transparent scientific review process, has now authorized three COVID-19 vaccines with the urgency called for during this pandemic, using the agency’s rigorous standards for safety, effectiveness, and manufacturing quality needed to support emergency use authorization.”

A blood donor deferral period does not exist for eligible individuals who have received the vaccine as it uses an inactivated common cold virus to deliver copies of the SARS-CoV-2 spike protein to trigger an immune response within the body. However, convalescent plasma should not be collected from individuals who have received an investigational vaccine unless that person meets all three of the following criteria identified in the [Investigational COVID-19 Convalescent Plasma Guidance](#) document for such individuals:

- “had symptoms of COVID-19 and a positive test result from a diagnostic test approved, cleared, or authorized by FDA; and
- received the COVID-19 vaccine after diagnosis of COVID-19, and
- are within 6 months after complete resolution of COVID-19 symptoms.”

This marks the third vaccine to receive EUA from the FDA and it can be used on adults aged 18 and older. It is a single dose vaccine and according to Janssen “demonstrated 85 percent effectiveness in preventing severe disease cross all regions studied (as part of the phase III ENSEMBLE trial), and showed protection

(continued on page 4)

The *ABC Newsletter* (ISSN #1092-0412) is published by America’s Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2021 by America’s Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher. (ABC members need not obtain prior permission if proper credit is given.)

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognize the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the healthcare system; promote partnerships, policies and programs that increase awareness about the need for blood donation; and serve as a thought-leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

### America’s Blood Centers

Chief Executive Officer: Kate Fry  
Chief Medical Officer: Rita Reik  
Editor: Mack Benton  
Subscriptions Manager: Leslie Maundy  
**Annual Subscription Rate: \$390**

Send subscription queries to  
[memberservices@americasblood.org](mailto:memberservices@americasblood.org)  
America’s Blood Centers  
1717 K St. NW, Suite 900, Washington, DC 20006  
Phone: (202) 393-5725  
Send news tips to [newsletter@americasblood.org](mailto:newsletter@americasblood.org).



## Janssen Vaccine Gets EUA (continued from page 3)

against COVID-19 related hospitalization and death, beginning 28 days after vaccination...The [c]ompany has begun shipping its COVID-19 vaccine and expects to deliver enough single-shot vaccines by the end of March to enable the full vaccination of more than 20 million people in the U.S. The Company plans to deliver 100 million single-shot vaccines to the U.S. during the first half of 2021” according to a Johnson & Johnson [news release](#).

(Sources: FDA Janssen EUA [Letter](#) 2/27/21; FDA [News Release](#), 2/27/21; Johnson & Johnson [News Release](#), 2/27/21) 💧

## RESEARCH IN BRIEF

**New Donors Responding to the Pandemic.** A report published in *Transfusion* examined the effect of the COVID-19 pandemic on “new donor registrations in the Netherlands.” Researchers used a national donor database to “[extract] new donor registrations for the period between the first week of 2020 (before the first confirmed COVID-19 case in the Netherlands in week eight) and week 20 (when several virus control measures were relaxed).” The study “compared the registration [s] with those in the same period in 2017, 2018, and 2019...[and] created timelines aggregated on a weekly level, reflecting new donor registrations and media appearance.” The authors explained that “[w]hile in the first eight weeks of the year there were more new donor registrations in 2018 and 2019 compared to 2020, this changed after the first nationwide infection prevention measures were imposed by the Dutch government in week 11...In the same week, Sanquin [the country’s national blood provider] announced that donors were needed because blood stocks were shrinking.” The study noted “the amount of newly registered donors increased, with peaks in week 13 (N = 4,226) and 16 (N = 4,123), while in the same weeks in 2017 to 2019 these numbers were on average 1,177 and 767, respectively...After these peaks, the number of new registrations declined and by week 20, they were back to levels comparable to 2017–2019.” The researchers discovered that “[c]ompared to 2019, the number of newly registered donors in 2020 grew from 23,997 to 36,573 (+52 percent)...The number of newly registered donors aged 55 or up in 2020 was 2,262, which was more than seven times higher than the 320 newly registered donors in 2018...The main peak in social media messages in 2020 [was] observed during weeks 11 and 12, when [there were calls] for donations due to blood shortages...[while] a smaller peak [was] observed in week 16, after [it was] announced (in week 15) [there] would be testing for SARS-CoV-2 antibodies...These social media peaks appear to precede the peaks in new donor registrations.” The study concluded that “[e]ven though blood donation during a pandemic might pose a health risk for the individual donor, [the] results show[ed] a large increase of new donors’ registrations, suggesting the motivations outweigh this health risk.”

**Citation:** Spekman, M.L.C., Ramondt, S., Quee, F.A., *et al.* New blood donors in times of crisis: Increased donation willingness, particularly among people at high risk for attracting SARS-CoV-2. *Transfusion*. 2021. Doi. [10.1111/trf.16334](https://doi.org/10.1111/trf.16334).

Contributed by Richard Gammon, MD, Medical Director at OneBlood 💧






## COVID-19 Convalescent Plasma Updates

**CCP Research.** *JAMA* [published](#) a systematic review and meta-analysis on the “Association of Convalescent Plasma Treatment with Clinical Outcomes in Patients with COVID-19.” It included 10 trials in India, Argentina, Bahrain, China, the Netherlands, Spain, and the United Kingdom. “Five of the randomized clinical trials (RCTs) terminated early; two were terminated early due to futility and three were terminated early due to slow recruitment... In this meta-analysis that included four RCTs published in peer-reviewed journals for the primary analysis and an additional six RCTs not published in peer-reviewed journals (five preprints and one press release) for the secondary analysis, treatment with convalescent plasma compared with placebo in combination with standard of care or only standard of care was not significantly associated with a decrease in all-cause mortality or with any benefit for other clinical outcomes among patients with COVID-19.” The researchers noted that limitations included, “3 of the 10 RCTs had some concerns or high risk of bias... the reporting of clinical outcomes, other than all-cause mortality, for the RECOVERY [trial] was insufficient and inconsistent regarding the use of definitions and relevant details across its COVID-19 treatment trials. The data were too limited to perform meaningful subgroup analyses... except for one RCT with outpatients, all patients were hospitalized with or without oxygen supplementation, indicative of moderate to critical COVID-19... The primary focus of this meta-analysis was on published RCTs. There are many ongoing trials (>100) assessing convalescent plasma that are at risk of being terminated early or never published, but a collaborative meta-analysis of all these data is underway.” ♦

### Convalescent Plasma: Industry Collections and Distributions



#### Upcoming ABC Webinars – Don’t Miss Out!

- **ABC SMT Journal Club Webinar** – March 31<sup>st</sup> from 1 – 2 p.m. (ET). The articles to be discussed on the webinar are [available](#) to ABC members on the Medical Issues Listserv.



**America's Blood Centers®**  
It's About *Life.*

## INSIDE ABC

*The programs and services described in the Inside ABC section are available to ABC member blood centers and their staff only, unless otherwise specified.*

### Call for ABC Committee Nominations Deadline Extended

ABC is encouraging all individuals who work at member centers to consider volunteering to serve on an ABC Committee. Interested individuals are invited to submit their committee nominations by completing the online [sign-up form](#) by Friday, March 12<sup>th</sup>. ABC relies on staff volunteers from member blood centers to do much of the great work that is accomplished by the association.

All current membership of the committees (listed below for your convenience) will sunset on March 31<sup>st</sup>.

#### Committees

- Bylaws Committee
- Membership Committee
- Leadership and Meetings Committee
- Public Policy Council
- Quality Committee
  - Quality Education Subcommittee
  - Regulatory Review Subcommittee – Blood
  - Regulatory Review Subcommittee - HCT/P
- Scientific, Medical, Technical Committee (SMT)
  - SMT Journal Club
  - SMT Publications Subcommittee (*Blood Bulletin*)

This is the call to continue the committees' work by volunteering to serve on a committee for a two-year term. We ask all Member Voting Representatives (MVRs) and their staff to review the listing of committees and their [descriptions](#) to determine interest in serving on a particular committee.

Thank you for your time, consideration, and commitment to helping ABC achieve excellence. Please feel free to contact [us](#) with any questions.

(Source: MCN 21-016, 2/11/21)

### Register Today for ABC's Annual Meeting

[Registration](#) is still open for the 59<sup>th</sup> America's Blood Centers Annual Meeting, which will be a virtual event March 8<sup>th</sup>–12<sup>th</sup>. Last year's meeting demonstrated the power of coming together as an industry to collaborate on strategies for the future of the blood industry. It is essential now more than ever, to bring executive, operational, and medical leadership together to focus on key issues which will ultimately impact blood center bottom-lines. The meeting will also feature a virtual Advocacy Day as member blood centers will have the opportunity to let their voices be heard with Congress. The schedule is available [here](#). ♦



## INFECTIOUS DISEASE UPDATES

### MALARIA

The World Health Organization (WHO) recently published consolidated [guidelines](#) for malaria. According to a WHO announcement, “[t]hese consolidated guidelines represent an important step in our efforts to deliver timely, evidence-based guidance to malaria-endemic countries,” said Dr Pedro Alonso, director of the WHO Global Malaria [Program]. “They will soon become a living resource that is updated periodically as new evidence becomes available, and as WHO guideline development groups bring forward proposals for new or revised recommendations.” The WHO added in the executive summary that these guidelines tend to be brief, evidence-based statements. “The first version of the *Guidelines for malaria* – available online only – is a compilation of existing WHO recommendations on malaria and supersedes two previous WHO publications: the *Guidelines for the treatment of malaria*, third edition and the *Guidelines for malaria vector control*. Four WHO guideline development groups focused on vector control and chemoprevention, treatment and elimination are currently convening to develop new or updated recommendations, and other groups will convene this year to address additional relevant topics. Recommendations on malaria will continue to be reviewed and, where appropriate, updated based on the latest available evidence through WHO’s transparent and rigorous guidelines review process.”

(Source: WHO Malaria Guidelines [Announcement](#), 2/16/21) ♦

### COMPANY NEWS

**Blood Centers of America, Inc. (BCA)** [announced](#) a partnership with Riot Games’ League Championship Series (LCS) to encourage COVID-19 Convalescent Plasma (CCP) donations from fans and players of esports who have been diagnosed with COVID-19 and have since recovered. LCS is the largest esports competition in North America according to the news release. “During the COVID-19 pandemic, blood centers have played a vital role in offering one of the few therapies approved for emergency use for patients hospitalized with the virus...CCP donors have been a critical part in continuing to ensure [the availability of this [therapy],” said BCA Chief Executive Officer (CEO) Bill Block in the news release. “As the need for CCP decreases, we are asking donors to consider donating their blood for other life-saving opportunities. The partnership with the LCS is a novel way to reach a population to help us continue to keep our blood supplies in a healthy state during the pandemic and beyond.” Matthew Archambault, head of Esports Partnerships for Riot Games North America and Oceania added, “[t]he LCS admires the work that BCA and its network continue to do, supporting pandemic relief and enhancing local communities’ ability to supply safe and reliable [blood and blood products]. We hope that, with the help of our fans, we can amplify the organization’s efforts.”

(Source: BCA and Riot Games [News Release](#), 3/3/21) ♦





## CALENDAR

**Note to subscribers:** Submissions for a free listing in this calendar (published weekly) are welcome. Send information to [newsletter@americasblood.org](mailto:newsletter@americasblood.org) or by fax to (202) 899-2621. (For a more detailed announcement in the weekly "Meetings" section of the newsletter, please include program information.)

### 2021

Mar 8-12. **ABC Annual Meeting (Virtual)**. Registration now [open](#).

April 15. **FDA Cellular, Tissue, and Gene Therapies Advisory Committee Meeting (Virtual)**. More details available [here](#).

May 4-6. **IPFA/PEI 27<sup>th</sup> International Workshop on Surveillance and Screening of Blood-borne Pathogens (Virtual)**. More details available [here](#).

May 12-13. **Elevate Your Donor Journey: ADRP Master Class in Finding Your XFactor (Virtual)**. More details available [here](#).

May 21-22. **64<sup>th</sup> Annual California Blood Bank Society Annual Meeting (Virtual)**. More details available [here](#).

Aug. 4. **ABC Medical Directors Workshop, Cleveland, Ohio**. More details coming [soon](#).

Aug. 5-6. **ABC Summer Summit, Cleveland, Ohio**. More details coming [soon](#).

Aug. 17-19. **2021 ADRP Conference, Kansas City, Mo**. More details coming [soon](#).

Sept. 15-17. **4<sup>th</sup> European Conference on Donor Health and Management, Hamburg, Germany**. More details available [here](#).

Oct. 16-19. **AABB Annual Meeting**. More details available [here](#). ♦

## CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC institutional members. There are charges for non-members: \$139 per placement for *ABC Newsletter* subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: [newsletter@americasblood.org](mailto:newsletter@americasblood.org)

## POSITIONS

**Operations Coordinator of Mobile Staging.** OUR WORK IS LIFE-SAVING...YOURS CAN BE TOO! Join our team as an Operations Coordinator of Mobile Staging! You will be responsible for overseeing all aspects of Bedford/Waco Mobile Staging and Centralized Scheduling. This includes development and implementation of all operational activities with emphasis on continuous process and improvement. Responsible for overseeing the preparation of payroll, supplies, equipment, vans, coaches, and finalization of mobile drive schedules needed for daily mobile operations. Responsible for overall management of mobile staging and scheduling technicians. If you have at least three years of Management experience and want to be a part of making a difference please apply [here](#) on our company website to be considered. Carter BloodCare is an EEO/Affirmative Action employer. Carter BloodCare provides equal employment opportunities (EEO) to all employees and applicants and will not discriminate in its employment

practices due to an employee's or applicant's race, color, religion, sex, sexual orientation, gender identity, age, national origin, genetic, and veteran or disability status. In addition to federal law requirements, Carter BloodCare complies with applicable state and local laws governing nondiscrimination in employment in every location in which the company has facilities. Carter BloodCare is a Pro Disabled & Veteran Employer. We maintain a drug-free workplace and perform pre-employment substance abuse testing.

**Donor Recruitment Manager (Blood Assurance, Nashville area).** Supervise and lead our Account Managers field recruitment efforts that build new and existing business in the assigned communities served by Blood Assurance. Assist in developing long-term community business partnerships, and coordinating internally with

(continued on page 9)



**POSITIONS** (continued from page 8)

all leadership levels to support or expand Blood Assurance recruitment efforts. Qualified candidates will have a bachelor's degree in business, marketing, or related field. Advanced communication skills, organizational skills, teamwork, customer service, follow up, networking, negotiation, and judgment. Also requires initiative, creative problem solving, conflict resolution, staff management and development. The hiring process begins with submitting an online employment application at [www.bloodassurance.org](http://www.bloodassurance.org). Blood Assurance is an EOE and Tobacco-Free work environment. All employment offers will be contingent upon successful completion of a positive background and employment references review and a negative drug test result.

**Operations Manager (Blood Assurance, Nashville area).** Manage our collection efforts in the greater Nashville, TN and surrounding areas. This position will be responsible for operational oversight of collection services for multiple collection teams in an assigned territory. Supervises staff in coordination with other department leaders and ensures compliance with all Standard Operating Procedures, FDA and AABB regulations. Monitors performance in the areas of productivity, proficiency, and customer service. Bachelor's degree required with some prior supervisory/management experience in blood banking is required. The hiring process with submitting an online employment application at [www.bloodassurance.org](http://www.bloodassurance.org). Blood Assurance is an EOE and Tobacco-Free work environment. All employment offers will be contingent upon successful completion of a positive background and employment references review and a negative drug test result.

**Medical Technologist or MLT (Blood Assurance, Nashville area).** Position in our Nashville lab location to perform basic to complex serologic patient testing and interpret result to determine donor-recipient compatibility. May consult and communicate with staff at other medical facilities, to resolve serologic problems and provide special units to transfusion recipients. Qualified candidates must have current State of Tennessee Medical Laboratory license and AS/BS Degree. Strong blood banking skills preferred. The hiring process begins with submitting an online employment application at [www.bloodassurance.org](http://www.bloodassurance.org). Blood Assurance is an EOE and Tobacco-Free work environment. All employment offers will be contingent upon successful completion of a positive background and employment references review and a negative drug test result.

**Specialist in Blood Banking (SBB) Certificate Program.** The LifeSouth Specialist in Blood Banking (SBB) certificate program, an independent educational program offering training in all aspects of blood banking and transfusion medicine, is accepting applications for the 2021-2022 class. Starting date is 06/14/2021. [Application](#)

deadline has been extended to 04/30/2021. Click [here](#) for additional information.

**Medical Technologist/ Transfusion Technical Specialist (Lee Health; Fort Myers and Cape Coral, FL).** \$10,000 Sign-on Bonus (2 years' experience) + \$2,500 relocation allowance if more than 50 miles from Lee Health, great benefits, and growth opportunities! Lee Health is looking for a talented and caring Medical Technologists/Transfusion Technical Specialists to join our exceptional team. We are a well-respected health system dedicated to providing a caring, compassionate, safe, and healthy environment. Now is the best time to join our caring, compassionate team at Lee Health in Fort Myers, Naples, and Cape Coral, Florida. To meet our growing needs, we are offering relocation and an exceptional hiring incentive package for qualified candidates selected to join our team! For more information, please call Anne at (239) 343-9989 or email at [Anne.Herndon@Lee-Health.org](mailto:Anne.Herndon@Lee-Health.org). Requirements: Bachelor's degree required. Five years' laboratory experience. DPR Supervisor Lab License. Clinical Laboratory Supervisor in Immunohematology. To learn more and apply, please visit: <https://jobs.leehealth.org/mtts>. Drug/Tobacco - free workplace. EOE

**Assistant Manager of Component Production (Carter BloodCare).** Functions: The Assistant Manager of Component Production will assist the Manager in all aspects of coordination of Component Production manufacturing functions. You will oversee daily operations, direct supervision of the production team, interviews, adhere to the fiscal budget, and any task to ensure efficient workflow with strong judgment and decisiveness. You will also collaborate with other blood centers on projects and corporate initiatives. Education: MLT ASCP or equivalent. Experience: Two years' supervisory experience in blood banking production, OR 5 years' supervisory experience in a government-regulated production environment, OR combination of education and experience. Two years' experience with computer blood banking/inventory management software. Carter BloodCare is an EEO/Affirmative Action employer. Carter BloodCare provides equal employment opportunities (EEO) to all employees and applicants and will not discriminate in its employment practices due to an employee's or applicant's race, color, religion, sex, sexual orientation, gender identity, age, national origin, genetic, and veteran or disability status. In addition to federal law requirements, Carter BloodCare complies with applicable state and local laws governing nondiscrimination in employment in every location in which the company has facilities. Carter BloodCare is a Pro Disabled & Veteran Employer. We maintain a drug-free workplace and perform pre-employment substance abuse testing. Click [here](#) to apply.

(continued on page 10)

## POSITIONS (continued from page 9)

**Medical Affairs Counselor (Scottsdale, AZ).** Vitalant is a nonprofit organization that collects blood from volunteer donors and provides blood, blood products and services across the United States. Under minimal supervision, this position is responsible for verbally counseling donors, physicians, and customers on the medical significance of infectious disease markers and responding to questions and concerns. Bachelor's degree or equivalent combination of education and experience required. Extensive working knowledge of infectious diseases preferred. RN license or Certification as a Medical Technologist by a recognized certifying agency preferred. Three years' experience in a healthcare environment required. To include: Experience in patient and/or donor education/counseling/communication. Please apply [here](#). EOE

**Phlebotomist/Collections Instructor.** Carter BloodCare is hiring an Instructor to our team in Bedford, Texas. The Instructor position is responsible for the training and continuing education of the Collection Services staff in all procedures involved in the allogeneic and special donation collection process. This includes but is not limited to medical history, donor lookup, phlebotomy, quality control, CPR, basic apheresis, and a minimum of one apheresis technology. This position is also responsible for ensuring that trainees receive adequate clinical experience, safely performing all required skills and successfully completing competency testing. They plan for and guide the learning process to help students achieve objectives required within the allotted time. They must have adequate transportation to travel. Please click [here](#) to apply. Carter BloodCare is an EEO/Affirmative Action employer. Carter BloodCare provides equal employment opportunities to all employees and applicants and will not discriminate in its employment practices due to an employee's or applicant's race, color, religion, sex, sexual orientation, gender identity, age, national origin, genetic, and veteran or disability status. In addition to federal law requirements, Carter BloodCare complies with applicable state and local laws governing nondiscrimination in employment in every location in which the company has facilities. Carter BloodCare is a Pro Disabled & Veteran Employer. We maintain a drug-free workplace and perform pre-employment substance abuse testing.

**Clinical Apheresis Registered Nurse.** The Clinical Apheresis Registered Nurse (CARN) collects leukocytes and performs therapeutic apheresis procedures for Carter BloodCare (CBC) clients in and around the Dallas/ Fort Worth area. The CARN follows CBC SOP's, assesses and monitors patient/donor while receiving an apheresis treatment; contacts patient physicians or a CBC Medical Director as situation warrants consults or order clarification, transfusion reactions and/or emergency situations; and ensures that excellent customer service is provided to

CBC customers. Education: RN with active unencumbered licensure in the State of Texas and CPR Certification. Experience: Minimum one (1) year nursing experience in a hospital setting, oncology unit, or clinic; Intensive care unit, dialysis, ER, oncology, and/or pediatric experience preferred; and Apheresis experience preferred. Please click [here](#) to apply. Carter BloodCare is an EEO/Affirmative Action employer. Carter BloodCare provides equal employment opportunities (EEO) to all employees and applicants and will not discriminate in its employment practices due to an employee's or applicant's race, color, religion, sex, sexual orientation, gender identity, age, national origin, genetic, and veteran or disability status. In addition to federal law requirements, Carter BloodCare complies with applicable state and local laws governing nondiscrimination in employment in every location in which the company has facilities. Carter BloodCare is a Pro Disabled & Veteran Employer. We maintain a drug-free workplace and perform pre-employment substance abuse testing.

**Medical Laboratory Technician.** The MLT 1 will report to the Medical City Dallas Heart & Spine Hospitals located in Dallas, TX. The incumbent will participate in all R&T Services activities including but not limited to: Perform testing/services associated with assigned departmental duties. By accomplishing these duties, the MLT 1 ensures daily operations in the R&T laboratories follow established guidelines, provide excellent service, and meet the needs of all R&T customers. Education: Associate Degree; and Medical Laboratory Technician, MLT (ASCP) certification or equivalent. Experience: Recent graduate from an accredited MLT program within last five years and currently board eligible. Must successfully obtain/maintain board certification (i.e., MLT (ASCP) or equivalent) and provided board certification documentation within 12 months of hire date. Please click [here](#) to apply. Carter BloodCare is an EEO/Affirmative Action employer. Carter BloodCare provides equal employment opportunities (EEO) to all employees and applicants and will not discriminate in its employment practices due to an employee's or applicant's race, color, religion, sex, sexual orientation, gender identity, age, national origin, genetic, and veteran or disability status. In addition to federal law requirements, Carter BloodCare complies with applicable state and local laws governing nondiscrimination in employment in every location in which the company has facilities. Carter BloodCare is a Pro Disabled & Veteran Employer. We maintain a drug-free workplace and perform pre-employment substance abuse testing.

(continued on page 11)

POSITIONS (continued from page 10)

OneBlood has exciting career opportunities available in the incredible state of Florida! Join our life saving mission in one of the following roles: **Reference Lab Manager (Ft. Lauderdale, FL)**. Valid and current Florida Clinical Laboratory Supervisor license in Immunohematology or Blood Banking and SBB certification required. Bachelor's degree in medical technology or related field with five (5) or more years' experience; prior management experience essential. **Compatibility Testing Lab Supervisor (Tallahassee, FL - \$5k Bonus Eligible)**. Bachelor's degree in medical technology, biological science, or related field and three plus years in a clinical laboratory, preferably in blood banking. Requires a current Florida Technologist license in Immunohematology or Blood Banking; FL Supervisor License preferred. **Medical Technologist (Tallahassee, FL - \$5k Bonus Eligible)**. A valid and current Florida Clinical Laboratory Technologist license in Immunohematology or Blood Banking is required. Prior blood banking experience preferred. Multiple shifts available. **Therapeutics Apheresis RN (Ft. Lauderdale, FL - \$5k Bonus Eligible)**. Current and valid Florida RN license, current BLS CPR certification, and a valid and clear driver's license is required. Flexibility in scheduling needed to meet the needs of the department; travel within the tri-county market in the South Florida area is required. OneBlood offers competitive benefits, including excellent shift differential pay for night and weekend schedules, Paid Time Off, Student Loan Repayment Program, a FREE medical coverage option, 403(b) Retirement Plan, company-paid annual CEU training & CE Broker account and MORE! To apply visit our OneBlood careers website at [www.oneblood.org/careers](http://www.oneblood.org/careers).

**Director of Technical Services (Morrisville, NC (Raleigh, NC Area))**. At The Blood Connection, our mission is to support our healthcare partners with adequate, safe, cost-effective blood supplies and services. We desire to be the community blood provider of choice. Position Overview: The Director of Technical Services (ENC) is responsible for supervising and directing the daily operations of the Technical departments in the ENC division: Hospital Services, Component Manufacturing (Biologics Processing), Immunohematology Reference Laboratory, as well as the HS couriers. Duties include: Developing and maintaining procedures. Supervising Reference Laboratory staff. Supervising Hospital Services staff. Supervising Component Manufacturing/Biologics Processing staff. Performing bench work as needed. Interfacing with hospital customers. This position requires general laboratory knowledge and skills as well as specialty (SBB) skills and is expected to perform tasks and well as supervise the performance of laboratory and other staff. Education Requirements: MT (ASCP) or equivalent. SBB strongly preferred. Licensure/Certification Requirements: Valid Driver's License. Experience Requirements: Previous supervisory experience required. Complete applications on <https://thebloodconnection.org/about-us/careers/> for consideration. 💧